Skip to main content

Table 1 Correlation of PRCC expression and clinical features of HCC patients

From: PRCC reduces the sensitivity of cancer cells to DNA damage by inhibiting JNK and ATM/ATR pathways and results in a poor prognosis in hepatocellular carcinoma

Variables Low (n = 33) High (n = 33) P-value
Gender, n (%)    0.741
 Female 6 (18.2) 5 (15.2)  
 Male 27 (81.8) 28 (84.8)  
Age, n (%)    0.218
 ≤ 50 14 (42.4) 19 (57.6)  
 > 50 19 (57.6) 14 (42.4)  
HBV, n (%)    0.689
 Negative 4 (12.1) 3 (9.1)  
 Positive 29 (87.9) 30 (90.9)  
Cirrhosis, n (%)    0.689
 No 4 (12.1) 3 (9.1)  
 Yes 29 (87.9) 30 (90.9)  
AFP, n (%)    0.032
 Negative, < 20 µg/L 14 (42.4) 6 (18.2)  
 Positive, ≥ 20 µg/L 19 (57.6) 27 (81.8)  
Tumor size, n (%)    0.398
 ≤ 3 cm 10 (30.3) 7 (21.2)  
 > 3 cm 23 (69.7) 26 (78.8)  
Tumor number, n (%)    0.492
 = 1 6 (18.2) 4 (12.1)  
 > 1 27 (81.8) 29 (87.9)  
PVTT, n (%)    0.046
 No 6 (18.2) 1(3.0)  
 Yes 27 (81.8) 32 (97.0)  
TNM stage, n (%)    0.030
 I and II 10 (30.3) 3 (9.1)  
 III and IV 23 (69.7) 30 (90.9)